8-KEarnings & ResultsExhibits & Filings

BIOGEN INC. 8-K Report, Financial Results (Jan 29, 2014)

Filed January 29, 2014For Securities:BIIB

Summary

Biogen Idec Inc. (BIIB) has filed an 8-K report on January 29, 2014, primarily announcing its fourth quarter and full-year 2013 financial results. The report references a press release (Exhibit 99) that details the company's performance for the periods ending December 31, 2013. Investors should review this press release for specific financial figures, revenue drivers, and any forward-looking statements or guidance provided by the company. While the 8-K itself is a brief filing, the incorporated press release is the key document for understanding Biogen Idec's operational and financial standing as of the end of 2013. It's important to note that the information furnished under Item 2.02 is not deemed 'filed' for certain regulatory purposes, meaning it doesn't carry the same legal implications as a formally filed document under Sections 18 or 33 of the Exchange Act or Securities Act.

Key Highlights

  • 1Biogen Idec announced its financial results for the fourth quarter and full year ended December 31, 2013, via a press release furnished as part of the 8-K filing.
  • 2The filing incorporates the press release (Exhibit 99) by reference, which contains the detailed results of operations and financial condition.
  • 3Investors should refer to Exhibit 99 for specific financial metrics, including revenue, earnings, and profitability for the reported periods.
  • 4The press release likely includes commentary on key product performance, pipeline updates, and future outlook, which are crucial for investor analysis.
  • 5The information is furnished under Item 2.02 and is not considered 'filed' for purposes of Section 18 of the Exchange Act, limiting liability for its content.
  • 6This filing serves as a notification to the market about Biogen Idec's latest financial performance.

Frequently Asked Questions

The main purpose of this 8-K filing is to publicly announce Biogen Idec's financial results for the fourth quarter and the full year ended December 31, 2013, by incorporating a press release that contains these details.

The detailed financial results are located in the press release furnished as Exhibit 99 to this 8-K filing. You should review Exhibit 99 for specific financial data and performance commentary.

When information is 'furnished' under Item 2.02, it is provided to the public but is not subject to the same liabilities or regulatory scrutiny as if it were 'filed' under certain sections of the Securities Exchange Act of 1934. This means the company has less legal exposure regarding the accuracy of the furnished information compared to officially filed documents.

Investors should look for key financial metrics such as revenue by product and geography, earnings per share (EPS), net income, operating expenses, and any guidance or outlook provided by the company for future periods. Information on the performance of key drugs like Tecfidera and Tysabri would also be critical.